Ayurcann Holdings Corp. (AYURF)
OTCMKTS · Delayed Price · Currency is USD
0.0176
0.00 (0.00%)
Aug 11, 2025, 8:00 PM EDT
Akoya Biosciences Revenue
Ayurcann Holdings had revenue of 7.56M CAD in the quarter ending March 31, 2025, with 16.50% growth. This brings the company's revenue in the last twelve months to 29.76M, up 27.96% year-over-year. In the fiscal year ending June 30, 2024, Ayurcann Holdings had annual revenue of 25.16M with 101.39% growth.
Revenue (ttm)
29.76M CAD
Revenue Growth
+27.96%
P/S Ratio
0.17
Revenue / Employee
n/a
Employees
n/a
Market Cap
3.54M USD
Revenue Chart
* This company reports financials in CAD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2024 | 25.16M | 12.67M | 101.39% |
| Jun 30, 2023 | 12.49M | 3.11M | 33.09% |
| Jun 30, 2022 | 9.39M | 1.75M | 22.96% |
| Jun 30, 2021 | 7.63M | 7.02M | 1,147.68% |
| Jun 30, 2020 | 611.83K | 607.65K | 14,537.06% |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| Elite Pharmaceuticals | 84.04M |
| Glass House Brands | 215.62M |
| American Oncology Network | 1.76B |
| Northwest Biotherapeutics | 1.47M |
| Silence Therapeutics | 27.17M |
| Global Cord Blood | 196.10M |
Ayurcann Holdings News
- 5 months ago - AYURCANN REPORTS ANOTHER RECORD SALES GROWTH IN Q2 2025 OF $13,363,509 - GlobeNewsWire
- 9 months ago - AYURCANN REPORTS ANOTHER RECORD SALES GROWTH IN Q1 2025 OF $14,760,268 AND PROVIDES CORPORATE UPDATE - GlobeNewsWire
- 9 months ago - AYURCANN TERMINATES BUSINESS COMBINATION - GlobeNewsWire
- 10 months ago - AYURCANN REPORTS FISCAL YEAR 2024 RECORD SALES OF $45,265,235 IN GROSS REVENUE, FEATURING ANOTHER 100% YEAR-OVER-YEAR INCREASE - GlobeNewsWire
- 1 year ago - Ayurcann Holdings Corp is entering into a business combination with Arogo Capital Acquisition Corp. and its subsidiaries at a combined enterprise value estimated to be U.S. $210 million. - GlobeNewsWire
- 1 year ago - AYURCANN REPORTS RECORD SALES IN Q3 2024 OF $11,655,360 FEATURING A 97% INCREASE IN GROSS REVENUE - GlobeNewsWire
- 1 year ago - AYURCANN REPORTS RECORD SALES IN Q2 2024 FEATURING A 141% INCREASE IN GROSS REVENUE - GlobeNewsWire
- 1 year ago - Ayurcann Provides a Corporate Update, Completes Debt Settlement and Grants Options and RSUs - GlobeNewsWire